NA
NBIX icon

Navellier & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Navellier & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,760
Closed -$1.75M – 292
2019
Q2 		$1.75M Sell
20,760
-4
-0% -$328 0.27% 98
2019
Q1 		$1.83M Buy
20,764
+757
+4% +$63.3K 0.28% 92
2018
Q4 		$1.43M Sell
20,007
-11,387
-36% -$1.09M 0.24% 89
2018
Q3 		$3.86M Buy
+31,394
New +$3.56M 0.5% 58

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Navellier & Associates's NBIX Position: Q3 2019 in Review

Navellier & Associates sold out of Neurocrine Biosciences (NBIX) in Q3 2019, closing a stake of 20,760 shares — an estimated $1.75M sold.

Navellier & Associates first reported a position in NBIX in Q3 2018 and held it in 4 quarters. The position peaked at $3.86M in Q3 2018. 332 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Navellier & Associates reported no remaining Neurocrine Biosciences position as of Q3 2019 after selling out during the quarter.
  • Navellier & Associates sold 20,760 Neurocrine Biosciences shares in Q3 2019, an estimated $1.75M.
  • Navellier & Associates first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 4 quarters.
  • Navellier & Associates's Neurocrine Biosciences position peaked at $3.86M in Q3 2018.
  • 332 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Navellier & Associates's 13F filing for Q3 2019, filed 16 Oct 2019.